3DMed, a Shanghai biotech, and Suzhou’s Alphamab have decided to join forces to develop KN035, a PD-L1 immuno-oncology drug discovered by Alphamab (Article, ChinaBio, MAR 4, 2016, View Source [SID1234523603]). Unlike most PD-L1 mAbs, KN035 is an injected product that the companies hope will be more effective and cause fewer side effects than the competition. 3DMed and Alphamab will develop KN035 equally. They expect to file for China clinical trial approval in Q2 and begin the trials before the end of the year, with US trials following later. Further details of the agreement were not disclosed.